As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
After activation by full agonists such as GLP-1,GLP-1R(1)couples with Gas activates adenolate cyclase(AC),and causes the accumulation of cAMP.With increasing cAMP levels, protein kinase A（PKA） and the exchange protein directly activated by cAMP-2(Epac-2) are also activated. PKA and Epac-2 trigger the closure of KATP and KV channels,which depolarizes the cell membrane opens voltage-dependent Calcium channels(VDCC) and causes Calcium influx and the promotion of insulin secretion by the islet beta cells.
Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA，1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.
Share：
Relevant news
marketing@medicilon.com
ABOUT
